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Abstract
Background: Pulmonary arterial hypertension (PAH) is a leading cause of mortality in systemic sclerosis (SSc). We
sought to determine survival, predictors of mortality, and health-related quality of life (HRQoL) related to PAH in a
large SSc cohort with PAH.
Methods: We studied consecutive SSc patients with newly diagnosed (incident) World Health Organization (WHO)
Group 1 PAH enrolled in a prospective cohort between 2009 and 2015. Survival methods were used to determine
age and sex-adjusted standardised mortality ratio (SMR) and years of life lost (YLL), and to identify predictors of
mortality. HRQoL was measured using the Short form 36 (SF-36) instrument.
Results: Among 132 SSc-PAH patients (112 female (85%); mean age 62 ± 11 years), 60 (45.5%) died, with a median
(±IQR) survival time from PAH diagnosis of 4.0 (2.2–6.2) years. Median (±IQR) follow up from study enrolment was 3.8
(1.6–5.8) years. The SMR for patients with SSc-PAH was 5.8 (95% CI 4.3–7.8), with YLL of 15.2 years (95% CI 12.3–18.1).
Combination PAH therapy had a survival advantage (p < 0.001) compared with monotherapy, as did anticoagulation
compared with no anticoagulation (p < 0.003). Furthermore, combination PAH therapy together with anticoagulation
had a survival benefit compared with monotherapy with or without anticoagulation and combination therapy without
anticoagulation (hazard ratio 0.28, 95% CI 0.1–0.7). Older age at PAH diagnosis (p = 0.03), mild co-existent interstitial
lung disease (ILD) (p = 0.01), worse WHO functional class (p = 0.03) and higher mean pulmonary arterial pressure at PAH
diagnosis (p = 0.001), and digital ulcers (p = 0.01) were independent predictors of mortality.
Conclusions: Despite the significant benefits conferred by advanced PAH therapies suggested in this study, the
median survival in SSc PAH remains short at only 4 years.
Background
Systemic sclerosis (SSc) is a multisystem autoimmune
disease, which occurs worldwide with a prevalence ran-
ging from 7/million to 489/million and an incidence ran-
ging from 0.6/million/year to 122/million/year [1]. SSc is
characterized by vasculopathy and excessive collagen
production, leading to skin and internal organ fibrosis.
As there are no effective disease-modifying agents or
cure, there is substantial morbidity and mortality in this
disease.
Despite an improvement over the last three decades,
morbidity and mortality in SSc remain high. This is
highlighted in a recent large study showing an age and
sex adjusted standardised mortality ratio (SMR) of 4.06
for newly diagnosed SSc patients, with 22.4 and
26.0 years of life lost (YLL) in women and men, respect-
ively [2]. Cardiorespiratory manifestations, in particular
pulmonary arterial hypertension (PAH), are the leading
cause of SSc-related death [3].
PAH occurs with a prevalence of 8–15% in SSc pa-
tients [4, 5]. It is characterised by abnormal vascular
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proliferation and remodelling, vasoconstriction and
thrombosis of the pulmonary vasculature, leading to ele-
vated pulmonary vascular resistance (PVR), ultimately
resulting in right heart failure and death [6]. PAH is
often asymptomatic in the early phases. Once symptom-
atic, the average life expectancy without treatment has
been 2–3 years [6]. Consequently, annual screening with
algorithms incorporating transthoracic echocardiogram
(TTE) and pulmonary function tests (PFTs) is recom-
menced [7].
Historically, treatment options for patients with SSc-
PAH are limited [6]. However, in the past decade, with
the introduction of new advanced pulmonary vasodilator
therapies used as monotherapy or combination therapy,
improvement in symptoms, function and survival has
been demonstrated [8, 9]. Currently, there are seven
PAH-specific therapeutic agents with regulatory ap-
proval available for use in Australia. These agents target
the prostacyclin pathway (epoprostenol and iloprost), ni-
tric oxide pathway (sildenafil and tadalafil) or the
endothelin pathway (ambrisentan, macitentan and
bosentan). Although not available for use in Australia,
Riociguat is available in other countries. In Australia, the
Pharmaceutical Benefit Scheme (PBS) subsidises mono-
therapy with one of these agents if prescribed by a phys-
ician in a government-designated PAH treatment centre.
Once on therapy, patients must demonstrate stability or
improvement relative to baseline parameters on two
tests (6 minute walk distance (6MWD), TTE or repeat
right heart catheterization (RHC)). The PAH-specific
therapy can be changed if the patient fails to maintain
stability on the aforementioned tests. Combined PAH-
specific therapy, using two or more drugs with different
modes of action can only occur by compassionate access
through hospital pharmacies or the manufacturers, or
at patients’ own expense. Anticoagulation in the treat-
ment of PAH is a contentious issue in SSc, with some
studies showing a survival benefit in patients with
idiopathic PAH (iPAH) and connective tissue disease
(CTD)-associated PAH [10, 11] and others not show-
ing a survival benefit [12]. Furthermore anticoagula-
tion in SSc is not without risk.
Despite an improvement in survival with these therap-
ies, survival in SSc-PAH remains well below that of
iPAH and CTD-PAH [13] with one-year, two-year and
three-year survival of 90%, 78% and 56%, respectively
compared with one-year, three-year and five-year sur-
vival in idiopathic PAH of 92%, 75% and 66%, respect-
ively [13, 14]. Survival in incident SSc-PAH may be
below this as these figures are derived from incident and
prevalent SSc-PAH cohort data, introducing a survival
bias. Not only does SSc-PAH affect patient survival, it
also has a significant impact on patients’ functional cap-
acity and health-related quality of life (HRQoL) [15, 16].
We sought to determine survival and HRQoL related to
incident SSc-PAH in a large cohort of Australian SSc pa-
tients, and to identify predictors of mortality.
Methods
Patient cohort
All patients fulfilled either the American College of
Rheumatology criteria for SSc or Leroy and Medsger cri-
teria for SSc [17, 18]. Patients included in this analysis
were from the Australian Scleroderma Cohort Study
(ASCS). The ASCS is a prospective multi-centre study of
risk and prognostic factors for cardiopulmonary out-
comes in SSc. The ASCS compromises 13 Australian
centres and has been approved by the human research
ethics committee of each of the participating hospitals
(St. Vincent’s Hospital, Melbourne Royal Adelaide
Hospital, Monash Medical Centre, Royal Perth Hospital,
The Queen Elizabeth Hospital, Sunshine Coast
Rheumatology, Prince Charles Hospital, John Hunter
Hospital, Royal North Shore Hospital, Royal Prince
Alfred Hospital, St George Hospital, Canberra
Rheumatology and the University of Tasmania). All pa-
tients provide written informed consent at recruitment.
Inclusion and exclusion criteria
All patients were screened annually for PAH with PFTs
and TTE. Any patient identified as at high risk of devel-
oping PAH, defined as systolic pulmonary arterial pres-
sure (sPAPTTE) of at least 50 mmHg and/or diffusing
lung capacity for carbon monoxide (DLCO) <50% pre-
dicted with forced vital capacity (FVC) >85% predicted,
without adequate explanation on high-resolution com-
puter tomography (HRCT) of the chest or ventilation-
perfusion (V/Q) scan of lung or both, underwent RHC.
We included all consecutive adult (age >18 years)
SSc patients from the ASCS between June 2009 and
June 2015, who were diagnosed with World Health
Organization (WHO) Group 1 PAH on RHC (mean
pulmonary arterial pressure (mPAP) of at least
25 mmHg and pulmonary arterial wedge pressure
(PAWP) <15 mmHg) [19].
Patients were excluded if they had WHO Group 2 or 3
pulmonary hypertension or Group 1 PAH but with co-
existing ILD with FVC <60% and abnormal HRCT of
the chest. V/Q scanning was used to exclude pulmonary
hypertension due to chronic thromboembolism.
Data collection
Patient demographics, clinical variables and cardiac and
pulmonary assessments were obtained from the ASCS
database. All physical examination and investigation data
were collected within one month of the first RHC, be-
fore starting pulmonary vasodilator therapy. Clinical
manifestations and autoantibody status were defined as
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present, if ever present from SSc diagnosis. Scleroderma
disease onset and disease duration were defined from
the date of onset of the first non-Raynaud manifestation.
Autoantibodies measured included anti-nuclear anti-
bodies (ANA), antibodies to extractable nuclear antigens
(ENA), anti-RNA polymerase III antibodies, anti-Scl-70
antibody and antiphospholipid antibodies (APLA). TTE
was performed according to standardised procedures
only at tertiary centres with expertise. Pulmonary in-
volvement was assessed by PFTs and HRCT.
Patient-reported outcome measures were collected an-
nually, including the SSc-specific health assessment
questionnaire (SHAQ) and the Medical Outcomes Study
Short Form-36 (SF-36), a functional assessment tool and
a health-related quality of life measurement tool, re-
spectively, which are both well-validated for use in SSc
[20]. These patient-reported outcomes (PROs) were
chosen as they are collected annually for each patient in
the ASCS.
Demographics and clinical manifestations were com-
pared between SSc patients who developed and those
that did not develop PAH. Furthermore, PRO scores
were compared between these two groups.
Outcome variables
The principal outcome variable was all-cause mortality.
The date of death was recorded. Where data were avail-
able, the exact cause of death was recorded. Patient status
(alive or dead) at the time of censoring (January 2016) was
confirmed by checking with the treating physician and
verified against hospital records. The secondary outcome
variables that we evaluated were the most recent SHAQ
score and the physical and mental component scores of
the SF-36 (PCS and MCS) following PAH treatment.
PAH therapy and other medications
All specific PAH therapies (endothelin receptor antago-
nists (ERA), phosphodiesterase-5-inhibitors (PDE5) and
prostacyclin analogues) and their combinations (mono-
therapy or combination therapy) were prescribed at the
discretion of the managing physician(s) and these
medications were recorded at each visit. Use of other
therapeutic agents such as anticoagulation (including in-
dication, date of initiation and target international nor-
malised ratio (INR) for warfarin, date and reason for
cessation of anticoagulation), antiplatelet agents, hydro-
xychloroquine (HCQ), mycophenolate mofetil (MMF),
hormone replacement therapy (HRT) and proton pump
inhibitors (PPIs) were also at the discretion of the man-
aging physician(s) and were recorded.
Statistical analysis
Patient characteristics at baseline are presented as
mean ± standard deviation for continuous variables
and as number (percentage) for categorical variables. All-
cause mortality was used for analyses because causes of
death could not always be confidently ascribed. Kaplan-
Meier (K-M) curves were used to estimate survival in pa-
tients with SSc-PAH. One-year, two-year and three-year
survival were assessed; date of RHC diagnosis of PAH was
considered the baseline from which survival was mea-
sured. The log-rank and Wilcoxon tests were used to
compare survival curves. The SMR was calculated using
the observed deaths in our SSc cohort and the expected
deaths in the Australian population, which was sourced
from the Australian Bureau of Statistics (ABS). YLL was
also calculated based on Australian life expectancy using
ABS data.
After testing to ensure proportionality of hazard, Cox
proportional hazards regression analyses were used to
determine univariable and multivariable predictors of
mortality. All variables a with p value ≤0.1 in univariable
analysis or variables with clinical face validity were se-
lected for inclusion in multivariable analysis. The results
were reported as hazard ratios (HR) with accompanying
95% confidence intervals (CI). Mixed effect linear regres-
sion was used to identify and quantify determinants of
the SHAQ score and the PCS and MCS of the SF-36 fol-
lowing PAH treatment. A two-tailed p value ≤0.05 was
considered statistically significant. All statistical analyses
were performed using STATA 14.0 (StataCorp LP,
College Station, TX, USA).
Results
Patient characteristics
Of the 1578 SSc patients enrolled in ASCS, 132 patients
were diagnosed with incident Group 1 SSc-PAH and in-
cluded in this study. Patient characteristics by PAH sta-
tus are summarised in Additional file 1: Table S1. SSc-
PAH patient characteristics and haemodynamic mea-
surements are summarised in Table 1. Our SSc-PAH co-
hort compromised predominantly women (84.9%) with
limited disease subtype (limited cutaneous systemic
sclerosis (lcSSc)) (68.9%) and a mean (IQR) follow-up
duration of 3.8 (1.6–5.8) years since ASCS recruitment.
At PAH diagnosis, the mean SSc disease duration was
14.1 ± 11.9 years, with no difference between disease
subtypes (p = 0.40). Anti-centromere ANA was the most
common autoantibody detected (51.6%), followed by
APLA (30%). Anti-Scl-70 was infrequent (7.4%).
Despite annual screening, the majority of patients at
PAH diagnosis were in WHO functional class II (17.4%)
or class III (59.9%) with a mean baseline 6MWD of
326.1 (±105.5) m. Hemodynamics measured at the time
of PAH diagnosis showed moderate PAH with an mPAP
of 35.6 (± 10.4) mmHg, mean right atrial pressure
(mRAP) of 8.3 (± 4.3) mmHg and mean cardiac index
(mCI) of 3.2 (± 1.9) L/min/m2. Mean DLCO at PAH
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diagnosis was 46.6% (± 13.5) predicted, and DLCO
corrected for alveolar volume (DLCO/VA) was 56.7%
(± 20.2) predicted. A pericardial effusion was present
at PAH diagnosis in 18.2% of patients.
Specific PAH therapy
All patients were treated with at least one specific PAH
medication. Considering the Australian PBS regulations,
in our study, the majority of patients (68.9%) were
treated with monotherapy (including sequential therapy)
and 31.1% with combination therapy (two or more ad-
vanced PAH therapies at the same time). Six patients re-
ceived upfront combination therapy at the time of PAH
diagnosis. The remainder of patients (31 patients
(26.5%)) on combination therapy received additional
therapy as “add-on” therapy due to functional deterior-
ation. Medications were altered at physician discretion
based on failure of the specific PAH therapy or adverse
effects.
As monotherapy, bosentan (68.1%) was the most com-
monly prescribed drug followed by sildenafil (15.9%).
Other monotherapy prescribed and its frequency in-
cluded ambrisentan (8.7%), macitentan (2.9%) and sitax-
entan (before its withdrawal) (2%). The most common
combination was bosentan and sildenafil (49.1%)
followed by bosentan and tadalafil (12.3%). Supplemental
home oxygen was used by 21.5% of patients.
Patients treated with combination therapy compared
with monotherapy had more severe PAH reflected by a
higher mPAP (39.4 (± 11.9) vs. 34.1 (± 10.4) mmHg,
p = 0.007), mPVR (6.2 (± 3.2) vs. 4.3 (± 2.5) Wood
Units, p = 0.003), lower DLCO percent than predicted
(41.4 (± 11.8) vs. 49.7 (± 13.5), p = 0.003) and the presence
of a pericardial effusion (36.6% vs. 11.3%, p = 0.001) at
PAH diagnosis. There was also a trend towards more
Table 1 Characteristics of patients with SSc-PAH
Characteristic Mean (± SD), number
(percent) or median (IQR)
Total number of patients 132
Female 112 (85%)
Age at PAH diagnosis, years 62.3 (± 10.9)











Follow-up durationb, years (median (IQR)) 3.8 (1.6–5.8)
Survival from PAH diagnosis, years (median (IQR)) 4.0 (2.2–6.2)






Anti-centromere pattern ANA 63 (51.6%)
Antiphospholipid antibodies (>ULN) 33 (30%)
RNA polymerase III positive 8 (11.4%)
Scl 70 positive 9 (7.4%)
WHO functional class at time of PAH diagnosis
Class I 3 (2.3%)
Class II 23 (17.4%)
Class III 79 (59.9%)
Class IV 12 (9.1%)
Baseline 6MWD, m 326.13 (±105.5)
Baseline mRAP, mmHg 8.3 (± 4.3)
Baseline mPAP, mmHg 35.6 (± 10.4)
Baseline PAWP, mmHg 10.5 (± 3.4)
Baseline mCI, L/min/m2 3.2 (± 1.9)
Baseline PVR, Wood units 8.7 (± 3.8)
Presence of a pericardial effusion at PAH diagnosis 24 (18.2%)
Mean DLCO, % predicted mL/min/mmHg 46.6 (± 13.5)




Combination therapy 41 (31.1%)
Warfarin therapyd 37 (28.5%)
Table 1 Characteristics of patients with SSc-PAH (Continued)
Hydroxychloroquine therapyd 12 (9.1%)
Antiplatelet agentc 48 (36.9%)
Mycophenolate mofetil therapyd 7 (5.4%)
Hormone replacement therapyd 16 (12.3%)
Proton pump inhibitord 105 (80.8%)
Home oxygend 28 (21.5%)
Abbreviations: SSc systemic sclerosis, PAH pulmonary arterial hypertension,
MCTD mixed connective tissue disease, ANA antinuclear antibody, ULN
upper limit of normal, WHO World Health Organization, 6MWD six-minute
walk distance, mRAP mean right atrial pressure, mPAP mean pulmonary
arterial pressure, PAWP pulmonary artery wedge pressure, PVR peripheral
vascular resistance, mCI mean cardiac index, DLCO diffusing capacity of the
lung for carbon monoxide, DLCO/VA DLCO adjusted for alveolar volume
aDisease duration from first non-Raynaud manifestation
bFollow-up duration was defined as years from study enrollment
cMonotherapy is treatment with a single PAH-specific therapy. Combination
therapy is treatment with more than one specific PAH agent from different
classes at one time
dTreatment ever following the diagnosis of PAH
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digital ulcers (68.3% vs. 49.4%, p = 0.06) at PAH diagnosis
in those commenced on combination therapy compared
with monotherapy. There was no difference in mRAP
(p = 0.37), mCI (2.7 (± 0.9) vs. 3.5 (± 2.1) L/min/m2,
p = 0.21), age at PAH diagnosis (p = 0.38) or disease
subtype (p = 0.47) (Additional file 1: Table S2) in
combination versus monotherapy.
Anticoagulation and other medical therapies
In our cohort of SSc-PAH patients, 28.5% were anticoa-
gulated with warfarin, 36.9% were on an antiplatelet
agent, 80.8% on a PPI, 12.3% on HRT, 9.1% on HCQ and
5.4% on MMF (for treatment of their skin disease). Nine
patients were on both warfarin and aspirin concurrently.
In those who were treated with warfarin, 54.1% were
initiated on warfarin specifically for the treatment of
PAH and 45.9% were placed on warfarin for another in-
dication following the diagnosis of PAH. Eleven PAH pa-
tients had to cease their anticoagulation after their PAH
diagnosis due to complications of warfarin therapy in-
cluding gastrointestinal bleeding (which accounted for
58.3% of reasons for stopping warfarin) and difficulty
monitoring the INR (INR target 1.5–2.5).
Patients on anticoagulation had more severe PAH
reflected by higher mPVR (6.2 (± 3.6) vs. 4.5 (± 2.5)
Wood units, p = 0.02), lower mCI (2.4 (± 0.7) vs. 3.7
(± 1.8) L/min/m2, p = 0.007), shorter 6MWD (291.3
(± 100.3) vs. 340.2 (± 104.9) m, p = 0.01), lower
mDLCO (42.3 (± 12.5) vs. 48.6 (± 13.5) mL/min/
mmHg, p = 0.05) and the presence of a pericardial ef-
fusion (36.1% vs. 12.9%, p = 0.003) at PAH diagnosis.
There was no difference in mRAP (p = 0.19), mPAWP
(p = 0.99), mDLCO/VA (50.0 (± 21.8) vs. 59.4 (±19.3) mL/
min/mmHg, p = 0.21), mPAP (39.5 (± 14.1) vs. 34.5 (±9.3)
mmHg, age at PAH diagnosis (p = 0.88), disease sub-
type (p = 0.85) or presence of digital ulcers (p = 0.94)
(Additional file 1: Table S2) in those who were antic-
oagulated compared with those who were not.
Of note, 37.5% of patients (6 patients) with a known
history of gastric antral vascular ectasia (GAVE), defined
as characteristic vascular lesions seen on endoscopy, but
without recent bleeding, were anticoagulated with war-
farin, while only 27.2% of patients (31 patients) with
PAH and no history of GAVE were anticoagulated. This
further highlights that many factors, not only GAVE, in-
fluence an individual physician’s decision to prescribe
anticoagulation in this group of patients.
Survival in SSc-PAH
SSc-PAH had a significant impact on survival (p < 0.001)
(Fig. 1). Over a median (± IQR) follow-up of 3.8 (1.6–
5.8) years from study enrolment, 60 (45.5%) patients
died with a median (± IQR) survival time from PAH
diagnosis of 4.0 (2.2–6.2) years. One-year, two-year,
three-year and five-year survival was 87.8%, 78.3%,
61.7% and 32.2%, respectively. The age and sex adjusted
SMR for patients with SSc-PAH compared with mortal-
ity in the general population was 5.8 (95% CI 4.3–7.3).
The overall YLL for both male and female patients due
to SSc-PAH was 15.2 years (95% CI 12.3–18.1). Men had
higher YLLs than women (17.0 years (95% CI 7.7–23.0)
compared with 15.4 years (13.8–20.3)). The majority of
Fig. 1 Survival in systemic sclerosis with pulmonary hypertension
(SSc-PAH). a Survival in SSc-PAH. b Survival with monotherapy vs
combination therapy. c Survival based on anticoagulation therapy
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deaths were directly related to PAH (70%), with PAH be-
ing a significant contributor in the remaining causes of
death (malignancy (13.3%), gastrointestinal complication
(10%), renal (3.3%), and infection (3.3%)).
In univariable analysis (Additional file 1: Table S3), fac-
tors associated with mortality included the presence of
calcinosis ever, worse WHO functional class, shorter
6MWD, higher mPAP and mPVR and lower DLCO at
PAH diagnosis, home oxygen use and lack of PPI use.
Independent predictors of mortality in SSc-PAH in
multivariable hazards regression analysis are summarised
in Table 2. To ensure model stability, a desired ratio of
independent-to-outcome variables was set at one to ten.
Older age at PAH diagnosis (HR 1.1, 95% CI 1.0–1.1,
p = 0.03), presence of mild ILD (HR 2.8, 95% CI 1.4–5.6,
p = 0.01), worse WHO functional class (HR 2.0, 95% CI
1.1–3.9, p = 0.03), higher mPAP at PAH diagnosis (HR 1.1,
95% CI 1.0–1.1 mmHg, p = 0.001) and presence of digital
ulcers ever (HR 3.1, 95% CI 1.4–7.2, p = 0.01) were pre-
dictive of mortality. The 6MWD was not predictive of
mortality. Using PAH monotherapy as our reference
group, the addition of anticoagulation to monotherapy
was associated with a trend towards survival benefit
(p = 0.09). Additionally, PAH combination therapy (all
cases were a combination of a PDE5 inhibitor and an
ERA) also showed a trend towards a survival benefit
compared with monotherapy alone (p = 0.10). Further-
more, combination PAH therapy, together with antic-
oagulation, provided the most significant survival
advantage with a 72% reduction in mortality com-
pared with pulmonary vasodilator monotherapy alone
(HR 0.28, 95% CI 0.1–0.7, p = 0.01).
Kaplan-Meier survival curves (Fig. 1) depict the
survival advantage with combination PAH therapy
compared with monotherapy (p < 0.001) and anticoagu-
lation compared with no anticoagulation (p < 0.003).
Mean time (± SD) to death was longer for patients who
were anticoagulated than those who were not (5.4 (± 2.5)
vs. 3.5 (± 2.1), p = 0.001) and for those on PAH combin-
ation therapy compared to those on monotherapy (5.2
(± 2.8) vs. 3.5 (± 1.9), p = 0.02). There was no differ-
ence in mean time to death in those with and with-
out APLA on anticoagulation (p = 0.68) or those with
limited versus diffuse disease subtypes (p = 0.56).
Patient-reported outcome measures in SSc-PAH
In relation to physical function, patients with SSc-PAH
had significantly lower SHAQ scores indicating signifi-
cant functional limitation in their daily activities com-
pared with SSc patients without PAH (Table 3).
Determinants of a better SHAQ score using mixed
Table 2 Independent predictors of mortality in SSc-PAH





Age at diagnosis of PAH, years 1.1 (1.0–1.1) 0.03
ILD on HRCT (FVC >60%) 2.8 (1.4–5.6) 0.01
WHO functional class 2.0 (1.1–3.9) 0.03
Pulmonary arterial pressure at PAH diagnosis, mmHg 1.1 (1.0–1.1) 0.001
Digital ulcers present ever 3.1 (1.4–7.2) 0.01
Specific PAH therapies and anticoagulation
Vasodilator monotherapy only reference reference
Vasodilator monotherapy and anticoagulation 0.39 (0.1–1.2) 0.09
Vasodilator combination therapy only 0.49 (0.2–1.2) 0.10
Vasodilator combination therapy and anticoagulation 0.28 (0.1–0.7) 0.01
Abbreviations: SSc systemic sclerosis, PAH pulmonary arterial hypertension,
WHO world health organization, ILD interstitial lung disease, HRCT high-resolution
computer tomography. FVC forced vital capacity, 6MWD six-minute walk distance,
mRAP mean right atrial pressure, mPAP mean pulmonary arterial pressure,
HCQ hydroxychloroquine
Table 3 Patient-reported outcomes in patients with SSc-PAH
compared to patients with SSc without PAH
Outcomes PAH No PAH P value
SHAQ domaina
Patient number 132 1447
Total score 3.2 ± 1.7 3.3 ± 2.1 0.74
Breathing 4.9 ± 2.5 2.3 ± 2.4 <0.001
Digital ulcers 1.9 ± 2.5 1.4 ± 2.4 0.02
Intestinal 2.8 ± 2.5 2.2 ± 2.4 0.002
Patient global assessment 5.1 ± 2.2 3.6 ± 2.4 <0.001
Pain 3.9 ± 2.6 3.4 ± 2.6 0.03
Vascular (RP) 3.3 ± 2.5 2.7 ± 2.5 0.01
SF-36 domainb
Physical functioning 35.7 ± 23.8 57.5 ± 28.9 <0.001
Role limitation, physical 27.2 ± 39.1 49.2 ± 43.4 <0.001
Role limitation, emotional 55.9 ± 44.9 67.3 ± 40.4 0.05
Social functioning 64.2 ± 27.7 70.5 ± 26.9 0.07
Mental health 66.1 ± 21.1 68.9 ± 20.2 0.28
Energy/vitality 38.6 ± 22.2 47.1 ± 24.1 0.01
Bodily pain 55.3 ± 28.8 60.7 ± 27.9 0.10
General health perception 36.6 ± 20.5 46.2 ± 22.7 0.01
Physical component score 31.7 ± 8.7 38.9 ± 11.6 <0.001
Mental component score 46.3 ± 10.7 46.3 ± 10.4 0.48
Systemic sclerosis (SSc)-specific health assessment questionnaire (SHAQ) and
Medical Outcomes Study Short Form-36 (SF-36) values are based on the
average of all instrument scores collected annually in the database. For those
with pulmonary hypertension (PAH), this includes only those scores that have
been collected since PAH diagnosis. For those without PAH this includes all
scores within the database for these patients. Raynaud's phenomenon (RP)
aThe SHAQ is a generic instrument measuring functional outcome validated
for use in SSc. The score ranges from 0 to 10, with 0 being no functional
limitation and 10 being severe functional limitation
bThe SF-36 form is a 36-item scale that measures eight domains of health
status. The final score is standardised to the general population normative
score of 50. The final score for each domain lies between 0 and 100, with 0
being the worst possible health and 100 the best possible health
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effects linear regression included older age at PAH diag-
nosis (coefficient −0.1, 95% CI 0.1 to 0.1, p = 0.02) while
the presence of GIT manifestations (coefficient 0.7, 95%
CI −2.7 to −0.1, p = 0.04) was associated with a worse
SHAQ score over time. Neither PAH-specific therapy
nor anticoagulation was associated with a significant
change in the total SHAQ score after treatment
(Table 4).
SSc-PAH patients had lower HRQoL scores across a
number of domains of the SF-36 at PAH diagnosis, par-
ticularly in physical functioning, role-physical and gen-
eral health and vitality, compared with the US normative
mean of 50, indicating decreased HRQoL [21] and sig-
nificantly lower SF-36 scores than SSc patients without
PAH (Table 3). Determinants of worse SF-36 PCS using
mixed effects linear regression included the presence
of digital ulcers (coefficient −3.7, 95% CI −7.2 to
−0.1, p = 0.04) and warfarin therapy (coefficient −3.7,
95% CI −7.1 to −0.3; p = 0.03). The presence of GIT
manifestations was associated with better SF-36 PCS
score (coefficient 4.7, 95% CI 0.9 to 8.6, p = 0.01).
Combination therapy was not associated with a signifi-
cant change in PCS scores after treatment (Table 4). De-
terminants of improved SF-36 MCS using mixed effects
linear regression included treatment with combination
PAH therapy (coefficient 5.2, 95% CI 1.3–9.1, p = 0.01)
(Table 4).
Discussion
In our SSc-PAH cohort, the median overall survival was
only 4 years with mortality of 45.5% over a follow-up
period from study enrolment averaging 3.8 years. The
one-year, two-year and three-year survival was 87.8%,
78.3% and 61.7%, respectively. Our results are similar to
those in a recent French study (90%, 78% and 50% sur-
vival) and lower than in a recent American study (93%,
88% and 75%), both of which also prospectively studied
survival in a cohort with incident SSc-PAH [13, 22]. The
majority of patients in the American study had New
York Heart Association (NYHA) functional Class II dis-
ease at PAH diagnosis, which may account for the higher
three-year survival in that study. Additionally, combin-
ation PAH therapy is more readily available in America
than in Australia, which may partly explain the better
survival in America. The NYHA functional class at PAH
diagnosis was similar to ours in the French study. Mor-
tality rates in the literature vary depending on whether
cohorts include patients with incident disease only or a
combination of those with incident and prevalent dis-
ease, with the potential of underreporting mortality in
cohorts with prevalent disease due to survival bias. To
our knowledge, this is the first paper to quantify YLL as-
sociated with SSc-PAH.
Of concern in our cohort, was that despite annual
screening for PAH, the majority of patients were in
WHO functional Class III at PAH diagnosis. This may
be because our screening algorithm missed patients with
early or mild PAH without a markedly elevated RVSP,
which may help to explain the relatively advanced stages
of PAH observed in our study. It is becoming increas-
ingly recognised that WHO functional class is an inde-
pendent predictor of mortality [13, 23], as was shown in
our cohort. The 6MWD was not associated with mortal-
ity in our study despite previous Australian data showing
an association [11], suggesting that 6MWD is a non-
specific outcome measure for PAH, and affected by the
other complications of SSc.
Another independent predictor of mortality in our co-
hort included older age at PAH diagnosis, which has
been reported in the literature to be a predictor of poor
survival, with one study indicating that patients
Table 4 Impact of PAH-specific therapy and anticoagulation on
health-related quality of life scores in SSc-PAH determined
through mixed effects linear regression modeling
Variables Coefficient (95% CI) P value
Determinants of SF-36 physical component score
Female gender 0.4 (−3.9, 4.7) 0.85
Age at PAH diagnosis, years 0.1 (−0.1, 0.2) 0.29
Diffuse disease subtype −0.3 (−3.8, 3.2) 0.87
Combination therapy 1.7 (−1.5, 5.0) 0.29
Anticoagulation therapy −3.7 (−7.1, −0.3) 0.03
GIT involvementa 4.7 (0.9, 8.6) 0.01
Digital ulcersa −3.7 (−7.2, −0.1) 0.04
Determinants of SF-36 mental component score
Female gender −3.5 (−8.6, 1.6) 0.18
Age at PAH diagnosis, years −0.1 (−0.2, 0.1) 0.67
Diffuse disease subtype −1.1 (−5.2, 3.0) 0.59
Combination therapy 5.2 (1.3, 9.1) 0.01
Anticoagulation therapy −2.5 (−6.6, 1.6) 0.22
GIT involvementa −1.6 (−6.2, 2.9) 0.48
Digital ulcersa 2.8 (−1.5, 7.1) 0.19
Determinants of SHAQ score
Female gender 0.3 (−0.5, 0.9) 0.46
Age at PAH diagnosis, years −0.1 (−0.1, −0.1) 0.02
Diffuse disease subtype −0.5 (−1.1, 0.2) 0.13
Combination therapy −0.3 (−0.8, 0.3) 0.38
Anticoagulation therapy 0.3 (−0.3, 0.9) 0.28
GIT involvementa 0.7 (0.1, 1.3) 0.03
Digital ulcersa −0.1 (−0.7, 0.5) 0.79
Abbreviations: SSc systemic sclerosis, PAH pulmonary arterial hypertension, GIT
gastrointestinal involvement, SHAQ scleroderma health assessment questionnaire
aDisease manifestations present if present at PAH diagnosis or at any follow-up
visit following PAH diagnosis
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diagnosed with PAH over the age of 60 years had three-
fold higher mortality risk than those diagnosed under
60 years of age [22].
Certain clinical manifestations such as the presence of
digital ulcers, calcinosis and telangiectasia have been re-
ported to predict those patients at a higher risk of devel-
oping PAH [24–26]. In our study, the presence of digital
ulcers was associated with greater mortality in SSc-PAH,
which may represent a common underlying pathogenic
mechanism involving endothelial dysfunction. Alterna-
tively, it may be an indicator of recurrent infections or
perhaps it identifies patients with a more severe vascular
phenotype with obliterative vasculopathy involving the
macrovasculature and microvasculature, manifesting in
PAH, digital ischaemia, ulcers and amputation.
The presence of moderate or severe ILD is in itself a
risk factor for death in SSc [27, 28]. In our cohort of pa-
tients, we excluded those with severe ILD defined as
FVC <60% and HRCT showing ILD, in whom PAH may
have occurred secondary to ILD. However, we included
patients with Group 1 PAH and co-existent mild ILD
defined by FVC > 60% and mild abnormalities or no ab-
normalities on HRCT. Mild ILD was present in 51 pa-
tients (38.6%) in our cohort and was predictive of death
in SSc-PAH. We postulate that the co-existence of these
two clinical manifestations could be due to shared
underlying pathogenic mechanisms leading to a more se-
vere clinical phenotype or that the occurrence in the
lung of two independent pathologic conditions increases
the risk of death.
There is evolving evidence to suggest that compared
with monotherapy, the treatment of PAH with combin-
ation therapy is associated with improved survival in
PAH. In small randomised trials and observational stud-
ies, combination therapy by means of “add-on” PAH
therapy has consistently shown a survival benefit in
PAH [11, 29, 30]. More recently, the treatment of PAH
with upfront combination therapy compared with mono-
therapy showed not only a survival benefit, but also re-
duced hospitalisation for worsening PAH and disease
progression [9].
Anticoagulation in PAH remains controversial despite
some observational studies showing a survival benefit
[1, 10]. The survival benefit is particularly apparent in
patients with iPAH as shown in the COMPERA study
[31], Interestingly, this study did not show a survival
benefit with anticoagulation in the non-idiopathic
PAH group, which included patients with PAH sec-
ondary to CTD, congenital heart disease and porto-
pulmonary hypertension. This may be due to the
inclusion of these subgroups all within one category
[31]. Furthermore, the REVEAL study showed no sig-
nificant survival advantage in iPAH or SSc-PAH with
the addition of anticoagulation [12]. Therefore, we
believe that further research is required to assess the
role of anticoagulation in PAH specifically associated
with SSc.
Australian data collected between 2002 and 2009 iden-
tified a survival advantage with warfarin therapy in pa-
tients with CTD-PAH, the majority of whom had SSc
[11]. In our study survival was similar if not worse than
in patients diagnosed and treated between 2002 and
2009. Two reasons may explain this. First, our study in-
cluded only patients with incident PAH whereas the pre-
vious study included both prevalent and incident cases,
thus increasing potential survival bias. Second, survival
in SSc-PAH is worse than that in CTD-PAH due to
other autoimmune rheumatic diseases such as systemic
lupus erythematosus and rheumatoid arthritis, so the
overall survival may have been increased due to the in-
clusion of CTD-PAH “survivors”.
There was improved survival in both studies with
anticoagulation as an adjunct to PAH therapy compared
with PAH therapy in isolation, despite patients on antic-
oagulation having had more severe PAH at baseline. We
propose that the benefit of anticoagulation relates to the
prevention of further micro-thrombotic phenomena oc-
curring in the pulmonary vasculature, which likely plays
an important role in the underlying pathogenesis of SSc-
PAH. The results of our study provide a rationale for a
randomised controlled trial evaluating anticoagulation as
adjunct therapy in SSc-PAH, which the trial Systemic
Sclerosis Pulmonary Hypertension Intervention with
Apixaban (SPHInX) (ACTRN12614000418673) aims to
resolve.
MMF has been shown to be associated with improved
survival in small groups of patients with SSc-PAH [32].
We were not able to replicate these findings as we only
had seven patients on MMF in our cohort, which may
be explained by the limited availability and expense of
MMF in Australia outside of tertiary hospitals until
2015. We were also interested in the relationship be-
tween the use of HCQ and survival in SSc-PAH given its
anti-platelet effect. Our study identified a trend towards
improved survival with HCQ, but this was not statisti-
cally significant. With only 12 patients on HCQ in our
cohort, our study may not have been sufficiently pow-
ered to show such an association.
Not only does SSc-PAH affect survival, it also has a
significant impact on patients’ functional capacity and
HRQoL [15, 16]. Functional limitations, as captured by
the SHAQ, were maintained over time with PAH ther-
apy in our cohort, without a significant improvement in
any specific domain, which is consistent with the litera-
ture [33, 34].
The physical component of HRQoL, as determined by
the SF-36 PCS, was also not improved with combination
PAH therapy in our cohort. However, combination PAH
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therapy was associated with a significant improvement
in the mental component of HRQoL as measured
using the SF-36 MCS. Reduction in mortality with
minimal change in HRQoL has been previously re-
ported in patients with CTD-PAH who are on PAH
therapy [30, 34, 35]. The lack of improvement in the
physical component of HRQoL following PAH treat-
ment may reflect the complex, multifactorial and in-
dividual nature of HRQoL, which is impacted upon
by a variety of factors that are difficult to measure
and adjust for.
We recognise that there are limitations to our study.
Lead-time bias may have contributed to the improve-
ment in survival in patients diagnosed as a result of an-
nual screening, with earlier implementation of PAH-
specific therapy and anticoagulation. We excluded pa-
tients with co-existent PAH and severe ILD to ensure
we captured only those patients with Group 1 PAH.
Therefore we did not assess whether severe ILD contrib-
uted to mortality, although we assume it would, as mild
ILD was a predictor of worse survival. In addition, treat-
ment was not randomised; rather, it was prescribed at
the individual physician’s discretion as there is no stand-
ard nationwide protocol for the SSc-PAH treatment.
Conclusion
Despite advanced therapy, the median survival in SSc-
PAH is only 4 years. In our study, the addition of anticoa-
gulation to standard combination therapy was associated
with a significant survival advantage, further pointing to
mechanisms involving endothelial abnormalities and small
vessel thrombosis in the pathogenesis of PAH. Although
there was no significant improvement in physical function
or in the physical components of HRQoL scores over
time, these remained stable with PAH therapy.
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